Literature DB >> 14623315

Identification of liver-intestine cadherin in hepatocellular carcinoma--a potential disease marker.

Bonnie W Wong1, John M Luk, Irene O Ng, Mei Y Hu, Kang D Liu, S T Fan.   

Abstract

Liver-intestine cadherin (LI-cad) is a non-classical cadherin, which is expressed during intestinal development, but absent in normal liver tissue. Our earlier investigation has detected overexpression of LI-cad in gastric adenocarcinoma and indicated its association with lymph node metastasis. Herein, we found in RT-PCR and TaqMan Q-PCR that LI-cad was identified in HCC cell lines, HuH-7, Hep-3B, and PLC/PRF/5, but not in MIHA and HepG2 non-tumorigenic cells. Immunofluorescence cytochemistry assay revealed that the LI-cad was predominantly expressed in cytoplasm of HCC cells, contrary to that of E-cad immunostain at the plasma membrane region. By testing against 18 pairs of HCC and adjacent non-tumor tissues, 13 cases (72.2%) showed over expression of LI-cad in HCC tissues, 2 cases (11.1%) were similar, and 3 cases did not yield detectable signal. None of the 6 normal liver specimens tested was positive with LI-cad. Taken together, LI-cad could be a potential disease marker for HCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623315     DOI: 10.1016/j.bbrc.2003.10.032

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.

Authors:  Felix H Shek; Ruibang Luo; Brian Y H Lam; Wing Kin Sung; Tak-Wah Lam; John M Luk; Ming Sum Leung; Kin Tak Chan; Hector K Wang; Chung Man Chan; Ronnie T Poon; Nikki P Lee
Journal:  Cell Oncol (Dordr)       Date:  2017-06-19       Impact factor: 6.730

2.  Altered expression of a Li-cadherin in gastric cancer and intestinal metaplasia.

Authors:  Weiguo Dong; Qiongfang Yu; Yu Xu
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

Review 3.  Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.

Authors:  Carmen Berasain; Saioa Goñi; Josefa Castillo; María Ujue Latasa; Jesús Prieto; Matías A Avila
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

4.  Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer.

Authors:  Reiko Ito; Naohide Oue; Kazuhiro Yoshida; Kyoko Kunimitsu; Hirofumi Nakayama; Kei Nakachi; Wataru Yasui
Journal:  Virchows Arch       Date:  2005-10-19       Impact factor: 4.064

5.  Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA.

Authors:  Jin Zhang; Qi-Sheng Liu; Wei-Guo Dong
Journal:  Med Oncol       Date:  2011-06       Impact factor: 3.064

6.  Dickkopfs and Wnt/β-catenin signalling in liver cancer.

Authors:  Sarwat Fatima; Nikki P Lee; John M Luk
Journal:  World J Clin Oncol       Date:  2011-08-10

7.  Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus.

Authors:  Andreas Weimann; Anja Rieger; Mathias Zimmermann; Monica Gross; Peter Hoffmann; Hortense Slevogt; Lars Morawietz
Journal:  Virchows Arch       Date:  2010-09-16       Impact factor: 4.064

8.  Cadherin 17 is a sensitive and specific marker for metanephric adenoma.

Authors:  Evgeny Yakirevich; Cristina Magi-Galluzzi; Zakaria Grada; Shaolei Lu; Murray B Resnick; Shamlal Mangray
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

Review 9.  Involvement of liver-intestine cadherin in cancer progression.

Authors:  Masaaki Takamura; Satoshi Yamagiwa; Yasunobu Matsuda; Takafumi Ichida; Yutaka Aoyagi
Journal:  Med Mol Morphol       Date:  2013-01-10       Impact factor: 2.309

10.  A protein-based set of reference markers for liver tissues and hepatocellular carcinoma.

Authors:  Stella Sun; Xin Yi; Ronnie Tp Poon; Chun Yeung; Philip J R Day; John M Luk
Journal:  BMC Cancer       Date:  2009-09-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.